Day 2 coverage:
Click here to read Reuters: Pharma 2022 Day 1 overview
Click here or the image below to read Reuters: Pharma 2022 Day 3 coverage
Having a continuous pulse on brand health is essential for pharmaceutical companies to inform strategic decisions and establish Key Performance Indicators (KPIs) in an ever-changing market
Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
Daniel Kohlstaedt, managing director of PurpleLeaf Strategy, with more than 18 years of experience in pharma, talks about his journey through the industry.
The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.
Developments in the oncology space in 2024 brought hope to both industry and patients.
Restoring Vision through Genetic Medicine
Advancing Analytics & QC from Pre-IND to BLA
